| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Muse Effective Treatment For Impotence In Radical Prostatectomy Patients MOUNTAIN VIEW, CA -- Oct. 21, 1998 -- Data published in this month’s issue of The Journal of Urology demonstrates that, in a clinical setting, Vivus, Inc.’s Muse(R) (alprostadil) allowed 70 percent of men with severe impotence to achieve an erection sufficient for intercourse. Of these men, 57 percent reported successful sexual intercourse during home treatment. All 384 patients studied had undergone radical prostatectomy at least three months before study entry and had identified the surgery as the cause of their erectile dysfunction. "I believe that Muse is an excellent treatment alternative for men after radical prostatectomy," said Ajay Nehra, M.D., assistant professor of urology, Mayo Clinic, Rochester, MN. "I would recommend Muse therapy in patients who sustain nerve injury during prostate surgery since it provides good quality erections with minimal side effects." Each year approximately 317,000 men are diagnosed with prostate cancer. In 1996 as many as 150,000 of these men chose to treat their cancer with radical prostatectomy and this number is expected to grow with greater patient awareness and early tumour detection through the use of prostate specific antigen (PSA) level testing. Even with the incorporation of nerve-sparing surgery techniques, erectile dysfunction occurs in many patients postoperatively. Muse therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacological agents via the urethra. Muse is applied into the urinary opening and is not for men with sickle cell trait, disease, or other blood disorders. One third of men reported genital pain, causing some to stop use. A few men reported dizziness and, less commonly, fainting. Related Links: Muse, Vivus, Inc.
|